Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07685405
Recruiting Observational

Identification of Circulating Biomarkers Associated With Extracellular Vesicles in Sarcomas

NCT07685405 · tracked via the Priya Life Science Italy tracker
Sponsor
Istituto Ortopedico Rizzoli
Phase
Observational
Started
2026-04-15
Last updated
2026-07-06

Condition(s) studied

Sarcoma, Ewing

Investigational drug(s) / intervention(s)

one blood sample3 blood samples

one blood sample: non onco

3 blood samples: onco

Study summary

The study involves blood samples from patients with Ewing's sarcoma to identify circulating biomarkers as a tool for the preclinical validation of innovative therapeutic approaches

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion criteria for cancer patients * Male and female patients of any age diagnosed with Ewing sarcoma. * Signed, study-specific informed consent form for the BIOVES study (cancer patients) Inclusion criteria for non-cancer patients * Male and female patients of legal age without a cancer diagnosis. * Signed, study-specific informed consent form for the BIOVES study (non-cancer patients) Exclusion Criteria: Patients who do not meet all inclusion criteria \-

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Istituto ortopedico Rizzoli Laboratorio di Ricerc Oncologica e Genomica funzioanle Bologna BO Recruiting

More Istituto Ortopedico Rizzoli trials in Italy

Assessment of Periprosthetic Bone Mineral Density in Patients Undergoing Total Knee Prosthesis of Different Design Recruiting
Comparison Between the Use of the Tensioner and Standard Surgical Technique for Ligament Balancing of Total Knee Prostheses Recruiting
Functional and Morphological Characterization of Multiple Osteochondromas Disorder Recruiting
Active Informed Consent: a New Solution to Improve and Objectively Test the Patient Understanding of Complex Surgical Procedures Proposals Recruiting
Evaluation of Clinical-functional and Radiographic Outcomes in Patients Who Underwent Meniscal Allograft Transplantation (MAT) at 10 Years. Recruiting

Other trials for the same condition

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07685405 on ClinicalTrials.gov ↗ ← All trials in Italy